Patients with a NPM1, IDH1, IDH2, or DNMT3A mutation had a complete response or complete response with incomplete hematologic recovery rate of more than 80%.
Researchers sought to determine whether second cancers associated with MPNs affect a patient’s prognosis, and whether cytoreductive or antiplatelet therapies affect outcomes.
Researchers conducted a meta-analysis of 7 studies involving NHL and 3 focused on MM to determine the role of occupational exposure to glyphosate in terms of risk.
Patients with acute myeloid leukemia with myelodysplasia-related changes diagnosed on the basis of dysplasia reported improved overall and event-free survival.
The development of a second hematologic malignancy after being diagnosed with chronic lymphocytic leukemia (CLL) appears to be uncommon, a retrospective study found.
Because lead-lined rooms are not always available, the SIERRA trial sought to establish whether mobile shields could provide a suitable alternative for reducing exposure rates.
Researchers summarized risk factors for relapse in acute myeloid leukemia, as well as current and prospective treatment strategies for minimizing relapse risk.
Researchers found that mutated EGR2 and TP53 were significantly associated with worse progression-free survival in patients with chronic lymphocytic leukemia.
A study found that grading systems for assessing toxicities from CAR-T therapy produced inconsistent scores, prompting a call for a more unified grading approach.
Researchers reported long-term follow-up results from the phase 3 RERISE study, which assessed the efficacy of radotinib compared with imatinib for CML treatment.
Patients who were treatment-naive had an overall response rate of 95%, while patients with relapsed/refractory disease had an overall response rate of 92%.
Researchers assessed whether adjusted asparaginase dosage helps reduce toxicity while maintaining sufficient asparaginase depletion in children with ALL.
Although prolonged periods of neutropenia are common following induction and intensification of chemotherapy, this study showed that pediatric patients with AML can be safely managed in the outpatient setting after resolution of neutropenia.
Eligibility criteria for this study included intermediate- or high-risk cytogenetics, and CR or CR with incomplete count recovery following induction chemotherapy.
Older age, body mass index above 30, and development of drug-induced diabetes mellitus were associated with increased risk for type 2 diabetes mellitus.
This study addressed the dearth of information on the incidence of psychiatric disorders related to corticosteroid-containing treatment in patients with hematologic malignancies.
Researchers sought to determine if nonmyeloablative HSCT conditioning was noninferior to myeloablative approaches in more vulnerable patients with AML.
Patients with acute myeloid leukemia and myelodysplastic syndromes reported similar quality of life irrespective of the conditioning regimen the received.
This study investigated whether T-cell gene-expression profiles and other molecular characteristics of T-cell populations were associated with CAR-T performance.
Patients receiving treosulfan and fludarabine experienced improved event-free and overall survival compared with patients receiving busulfan and fludarabine.
